C(O)—, —N($R^{A3}$)—C(O)O—, —C(O)—N($R^{A3}$)—, —N($R^{A3}$)C(O)N($R^{A3}$)—, —S—, —SO—, —$SO_2$—, —$S(O)_2N(R^{A3})$—, or —$N(R^{A3})SO_2$— wherein $R^{A3}$ is selected from hydrogen or (1-2C)alkyl; and

Z is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C) alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;

and wherein Z is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, $NR^{A6}R^{A7}$, —$(CR^{A4}R^{A5})_p$—$NR^{A6}R^{A7}$ (wherein p is selected from 1, 2 or 3), (1-4C) alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^{A6}R^{A7}$, $NR^{A4}C(O)R^{A5}$ $NR^{A4}S(O)_2R^{A5}$ and $S(O)_2NR^{A4}R^{A5}$; wherein $R^{A4}$ and $R^{A5}$ are each independently selected from hydrogen or (1-4C) alkyl; and wherein $R^{A6}$ and $R^{A7}$ are each independently selected from hydrogen, (1-4C)alkyl, (1-4C)alkylamino, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or $R^{A6}$ and $R^{A7}$ can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z is optionally further substituted by halo, cyano, nitro, hydroxy, caboxy, amino, (1-2C)alkoxy, or (1-2C)alkyl;

$R_2$ is a substituent group selected from hydrogen, halo, cyano, nitro, hydroxy or $R_2$ is selected from:

(i) —$C(O)OR_{2A}$, wherein $R_{2A}$ is selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C)alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent groups selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C) alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl;

(ii) —$C(O)NR_{2B}R_{2C}$; wherein $R_{2B}$ and $R_{2C}$ are each independently selected from hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, aryl, aryl-(1-2C)alkyl, heteroaryl, heteroaryl-(1-2C) alkyl, heterocyclyl or heterocyclyl-(1-2C)alkyl, each of which is optionally substituted by one or more substituent selected from oxo, halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, or (1-4C)alkanoyl;

(iii) —$C(O)NR_{2D}NR_{2B}R_{2C}$; wherein $R_{2D}$ is selected from hydrogen or (1-6C)alkyl and $R_{2B}$ and $R_{2C}$ are as defined above;

(iv) tetrazolyl;

(v) triazolyl;

(vi) —$B(OR_{2F})(OR_{2G})$, wherein $R_{2F}$ and $R_{2G}$ are each independently selected from hydrogen, (1-6C)alkyl or $R_{2F}$ and $R_{2G}$ are linked such that, together with the B and O atoms, they form a 5 or 6-membered heterocyclic ring, which is optionally substituted by (1-2C)alkyl; or

(vii) trifluoromethylketone;

$R_3$ is absent or a substituent group selected from halo, cyano, nitro, hydroxy or a group of the formula:

—$Y^2$—$X^2$—$Z^2$

wherein

$Y^2$ is absent or a linker group of the formula $[CR^{C1}R^{C2}]_n$— in which n is an integer selected from 1 or 2, and $R^{C1}$ and $R^{C2}$ are each independently selected from hydrogen or (1-2C)alkyl;

$X^2$ is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —$CH(OR^{C3})$—, —$N(R^{C3})$—, —$N(R^{C3})$—C(O)—, —$N(R^{C3})$—C(O)O, —C(O)—$N(R^{C3})$—, —$N(R^{C3})C(O)N(R^{C3})$—, —S—, —SO—, —$SO_2$—, —$S(O)_2N(R^{C3})$—, or —$N(R^{C3})SO_2$— wherein $R^{C3}$ is selected from hydrogen or (1-2C) alkyl; and

$Z^2$ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C) alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl;

and wherein $Z^2$ is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, $NR^{C4}R^{C5}$, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, $C(O)NR^{C4}R^{C5}$, $NR^{C4}C(O)R^{C5}$, $NR^{C4}S(O)_2R^{C5}$ and $S(O)_2NR^{C4}R^{C5}$; wherein $R^{C4}$ and $R^{C5}$ are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or $R^{C4}$ and $R^{C5}$ can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;

and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on $Z^2$ is optionally further substituted by halo, cyano, nitro, hydroxy, caboxy, $NR^{C6}R^{C7}$, (1-2C)alkoxy, or (1-2C) alkyl; wherein $R^{C6}$ and $R^{C7}$ are selected from hydrogen or (1-2C)alkyl;

with the proviso that when n is O, Q is not absent.

or a pharmaceutically acceptable salt thereof.

**2**. A combination product according to claim **1**, wherein the β-lactamase inhibitor is a compound of Formula I and Q is O.

**3**. A combination product according to claim **1**, wherein the β-lactamase inhibitor is a compound of Formula I and $X_4$ and $X_5$ are carbon.

**4**. A combination product according to claim **1**, wherein the β-lactamase inhibitor is a compound of Formula I and $R_3$ is absent or a substituent group selected from halo, cyano, nitro, hydroxy, carboxy, amino, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl or (1-4C)alkanoyl.

**5**. A combination product according to claim **1**, wherein the β-lactamase inhibitor is a compound of Formula Ib, shown below:

Formula Ib